3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
14
Phase 1
14
Phase 1/2
7
Phase NA
3
Phase 3
3
Status
Completed
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Lymphoid
2
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Renal Cell
3
Kidney Neoplasms
2
Urogenital Neoplasms
1
Neoplasm Metastasis
1
Interventions
Docetaxel
77
Radiotherapy
73
Prednisone
66
Leuprolide
51
Goserelin
49
Gemcitabine
49
Cisplatin
48
bicalutamide
46
enzalutamide
43
Androgen Antagonists
36
pembrolizumab
32
Abiraterone Acetate
31
Mitomycin
29
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
28
Magnetic Resonance Spectroscopy
28
Carboplatin
27
Flutamide
25
Nivolumab
24
Triptorelin Pamoate
23
Sunitinib
23
apalutamide
22
Radiation
22
Doxorubicin
20
darolutamide
19
abiraterone
18
Gonadotropin-Releasing Hormone
18
cabozantinib
17
atezolizumab
16
Specimen Handling
16
Radiosurgery
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
temsirolimus
×
Genitourinary
×
Clear all
NCT00631371
2016-04-27
INTORACT
Pfizer
Phase 3
Completed
791 enrolled
11 charts
NCT00474786
2013-11-21
INTORSECT
Pfizer
Phase 3
Completed
512 enrolled
16 charts
NCT00065468
2012-10-25
ARCC
Pfizer
Phase 3
Completed
626 enrolled
18 charts